Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III randomized double-blind placebo-controlled study of HZBio1 in gout with inadequately controlled serum uric acid after oral therapy
CTR20254714Phase 3Active
- Sponsor
- Chongqing Paijin Biotechnology
- Start
- Dec 2025
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of HZBio1 in gout, sponsored by Chongqing Paijin Biotechnology. Started Dec 2025; status: active.
02
Drugs
HZBio1
03
Conditions
gout
Beyond the preview
Go deeper on CTR20254714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254714.